Page 3 - Human Study News Today

/PRNewswire/ -- Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy, today announced the...

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Although marijuana leads to the munchies, it is paradoxically tied to lower BMI. Following promising mouse studies, researchers will test the synthetic cannabinoid nabilone for weight loss in humans.

Artists So Kanno, ORLAN, and others give us an idea of how it all comes together, and give their advice for those looking to get a start.

ABBVie will present results from nearly 30 abstracts across eight types of cancer during the upcoming American Society of Hematology Annual Meeting in Atlanta, Georgia . "We are dedicated to transforming standards of care for people living with blood cancers," said Mohamed Zaki M.D., Ph.D, vice president and global head of oncology development, AbbVie. "The data we are presenting at the ASH Annual Meeting build on ...

/PRNewswire/ -- AbbVie (NYSE: ABBV) will present results from nearly 30 abstracts across eight types of cancer during the upcoming American Society of...

/PRNewswire/ -- CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies,...

Share this article Share this article KRAKOW, Poland, June 1, 2021 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU) today announced that the latest results from the DIAMOND-01 clinical trial (CLI24-001; clinicaltrials.gov identifier NCT03008187) will be disclosed through poster presentations at both the upcoming American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) Virtual Congresses, to be held on June 4-8, and June 9-17, respectively. DIAMOND-01 is a First-in-Hu...

Results Confirmed Manageable Safety Profile of SEL24/MEN1703 and Showed Preliminary Efficacy in Relapsed/Refractory Acute Myeloid Leukemia Data to be Presented at ASCO and EHA Virtual

Merck Highlights Scientific Data at 2021 ASCO Annual Meeting Across More Than 20 Cancer Types From Broad Oncology Research Program First-Time Data for KEYTRUDA ® in Early-Stage Kidney Cancer and for LYNPARZA ® in Early-Stage Breast Cancer To Be Featured in ASCO Plenary Session New Data To Be Presented for KEYTRUDA in Advanced Gastric Cancer Merck known as MSD outside the United States and Canada, today announced that data spanning more than 20 cancer types from its oncology research program w...